MPF Rebuilds and Reimagines My QuitBuddy as the Nation's Leading Digital Cessation Companion
SYDNEY, June 11, 2025 /PRNewswire/ -- On World No Tobacco Day, Miroma Project Factory (MPF) launched the next evolution of My QuitBuddy, Australia's flagship smoking and vaping cessation app, commissioned by the Department of Health, Disability and Ageing. The My QuitBuddy app aims to help Australians kick the habit for good.
Modernised, rebuilt, and ready to support a new generation of quitters, this multi-phase redevelopment is the most significant upgrade in the app's history. MPF has led the product redesign, technical delivery, and strategic roadmap across seven structured phases - replatforming, refreshing, and relaunching a vital public health tool for the digital age.
"The My QuitBuddy app has already helped more than 1 million Australians quit smoking and vaping since it was first released in 2012, and the new developments will make it even easier for people to kick the habit," said Mark Butler, Minister for Health, Disability and Ageing. The upgraded app is part of a suite of measures the Australian Government has put in place to tackle the health scourge of tobacco and nicotine use, particularly to support priority populations such as young people to quit smoking and vaping."
Originally launched in 2012 to support a broad range of smokers, My QuitBuddy has evolved to address broader and more complex needs, including support for people who vape. The app features stronger motivational goal setting, badges and achievements, challenges for testing situations and a more intuitive user experience; all designed to make quitting feel more achievable - and more personal.
MPF was first engaged in late 2023, to reimagine the journey to be smoke/vape free, initially to restore the Android version of My QuitBuddy. This was followed by five additional phases from stabilising the app and migrating to a new environment (Flutter), which laid the foundation for a modern, cross-platform foundation without altering core functionality.
Launching today marks the most transformative release that MQB has gone through. A full reimagining of the app with multiple quit pathways, advanced tracking, enhanced gamified features, dynamic onboarding, and personalised messaging for a wide range of users.
"Every click, swipe, and prompt in My QuitBuddy 2.0 is grounded in behavioural science and backed by deep user insight," said Kat Robinson, Global CEO of MPF. "We're not just building a better-looking app, we're building a better quit journey for every Australian."
Built for Real Impact and Reach
The updated My QuitBuddy app has been shaped by years of behavioural insights, user testing, and direct feedback from the quitting community. From cravings to milestones, every screen is designed to support users when it matters most - without judgment, pressure, or gimmicks. The result is a flexible, evidence-informed platform that encourages long-term behaviour change while generating meaningful insights into user engagement, relapse patterns, and help-seeking behaviours.
These insights not only guide future improvements but also provide public health teams with a clearer understanding of how different quit strategies perform across priority populations, including young vapers, dual users, and those using NRT (Nicotine Replacement Therapy) as part of their quitting strategy.
Whether users are quitting cold turkey, tapering off, or using NRT, My QuitBuddy now offers them tailored support, contextual encouragement, and real-time tools to track progress, celebrate wins, prove their resilience and recover from slips. Features include:
Daily motivational messages and nudges, related to your personal circumstances
Richer community features and reactions, with selected featured messages
Challenges you can set for yourself
Games and distractions to help with cravings or withdrawal symptoms
Achievements and badges that recognise how far you have come
The app's new pathway selections support complex quit journeys - including simultaneous smoking and vaping cessation or staggered approaches - ensuring each user receives a personal, adaptive experience from day one.
MPF now turns their efforts to continual support, enhancement, and performance monitoring. My QuitBuddy is positioned to remain a world-class cessation tool - stable, scalable, and ready to adapt with evolving policy and public health needs.
Backed by MPF's long-standing partnership with the Department of Health, Disability and Aging; My QuitBuddy is more than a support app - It is a model for meaningful digital health tools, practical, evidence-based, and deeply human.
DOWNLOAD ANDROID HERE
DOWNLOAD IOS HERE
About My QuitBuddy
My QuitBuddy is a free smoking and vaping cessation app funded by the Australian Government and developed by Miroma Project Factory. Since 2012, the app has supported millions of Australians on their quit journey. Now fully rebuilt with advanced personalisation, flexible quit pathways, and updated gamified elements, My QuitBuddy is one of the most comprehensive digital cessation tools available.
About Miroma Project Factory (MPF)
MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, read about My QuitBuddy here.
Press Contact:Miroma Project Factoryinfo@theprojectfactory.com
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mpf-rebuilds-and-reimagines-my-quitbuddy-as-the-nations-leading-digital-cessation-companion-302478657.html
SOURCE Miroma Project Factory
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Thousands Sickened, 9 Killed from Virus Outbreak at 4 Popular Vacation Destinations
An urgent travel warning has been issued for four popular European hotspots, as an outbreak of hepatitis A has sickened more than 2,000 people and caused 9 deaths The European Center for Disease Prevention and Control has reported a "significant increase" in the wildly contagious virus, which causes a liver infection Common instances of transmission include eating food that was prepared by someone with the virus who did not wash their hands after using the bathroom, or by eating shellfish from contaminated waterAn urgent travel warning has been issued for four popular European vacation hotspots due to a virus outbreak that's sickened thousands and caused nine reported deaths. The European Center for Disease Prevention and Control has reported a 'significant increase' in hepatitis A infections in Austria, Czechia, Hungary and Slovakia between January and May 2025, with cases totaling 2,097. Hepatitis A, the Mayo Clinic explains, is a 'highly contagious' liver infection caused by a virus which "spreads when infected stool, even just tiny amounts, enters the mouth of another person (fecal-oral transmission)." Transmission sources include consuming food or water that's contaminated or has been prepared by someone with the virus who didn't wash their hands after using the bathroom. The virus is durable, and can stay alive on surfaces 'for a few months.' It can also spread by eating raw shellfish from sewage-contaminated water. Slovakia — whose lakeside resorts are popular vacation destinations — has a recorded 880 cases so far this year; Hungary has reported 530 cases, largely among adults. While Austria has only 87 confirmed cases, the country has also reported three deaths. The outbreak has been the most devastating in Czechia, where six have died; The ECDC reports that 'young children [are] the most affected group.' Although Germany is not considered a part of the outbreak, the agency did note that three cases have been identified which match the profiles of cases in Hungary and Austria. The ECDC says the outbreak is largely spreading via 'person-to-person transmission within connected social networks or geographical areas, rather than multiple unrelated outbreaks.' 'Circulation of the virus is high among people living in poor sanitary conditions, people who inject drugs, and people experiencing homelessness,' the agency says. Responding to the outbreaks, Czech Republic's state health institute director and chief hygienist Dr. Barbora Macková said, 'In the current epidemiological situation, we recommend getting vaccinated before the start of holidays and vacations,' per The Daily Mail. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Not everyone who gets infected will get sick, the Mayo Clinic notes, adding that symptoms may start weeks after infection. These include the hallmark symptoms like jaundice (yellowing of skin and the whites of the eyes), abdominal pain that's focused on the right side of the stomach — near the liver — and dark urine. Gastrointestinal symptoms (nausea, vomiting and diarrhea) can accompany the virus, as well as fever and fatigue. Getting the hepatitis A vaccine within two weeks of suspected exposure may help prevent sickness. Read the original article on People
Yahoo
3 hours ago
- Yahoo
I'm an expert in crafting public health messages: Here are 3 marketing strategies I use to make Philadelphia healthier
In Philadelphia, the leading causes of death are heart disease, cancer and unintentional drug overdose. While some of these deaths are caused by things out of our control – like genetics – many are largely preventable. Preventable deaths are the result of a series of decisions. Whether a person decides to smoke, eat lots of fried foods or be a couch potato, their decisions – sometimes unconsciously – can affect their health. I'm a health communication expert and public health researcher at Temple University in North Philadelphia. I began working in public health in the late 1980s at the beginning of the HIV/AIDS epidemic, and before that I worked in marketing and public relations. I have spent my career thinking about how health decisions are like many of the decisions consumers make each day around which products to buy. One key difference with health decisions is the inherent risks involved. There isn't much risk in trying a new brand of cereal, but there is risk in riding a motorcycle without a helmet. Many people have a 'that won't happen to me' attitude when making a decision that involves risk. This element of 'risk perception' has guided my interest in health decisions and how to use commercial marketing techniques – the same ones companies use to sell products – to encourage people to get vaccinated, get a colonoscopy or get treated for a medical condition. One strategy I use is segmentation analysis. Segmentation analysis is the process of looking at groups of people who may look like they are all similar on the surface – such as Black women from North Philadelphia – and then breaking them into smaller groups based on differences in their attitudes, beliefs or behaviors. Looking at these 'psychographics' instead of demographics like age or sex can help public health communication researchers better understand how to communicate effectively. For example, I led a study in 2021 that looked at how connected transgender women living in Philadelphia and the San Francisco Bay Area felt to other members of the trans community. We wanted to see if messaging about PrEP, or pre-exposure prophylaxis, the medication used to prevent HIV infection, would need to be different depending on how connected they felt. We found that participants who were more engaged with the trans community were not only more knowledgeable about PrEP, but they were also more likely to see the benefits of using it compared with those who were less engaged. This indicates that strategies to reach those not as connected may need to include, for example, providing more basic information about what PrEP is and how it works. Another powerful marketing tool that I use is a process known as perceptual mapping and vector message modeling. Using simple survey answers, we can mathematically model how people are thinking about a health decision and present it in a three-dimensional map. Similar to how someone might think about the relationship between where cities or countries are in relation to each other – such as where Philadelphia is in relation to New York or Chicago – we can take answers from a survey and convert them into distances. We ask people to agree or disagree to statements about the benefits or barriers to a decision and enter their responses into a computer program to create the map. We can then do vector message modeling, which shows how to move the group toward the desired decision. Think back to high school physics when you may have learned about the amount of force, or pushing and pulling, needed to move one object toward another. Vector message modeling helps us figure out which beliefs to push or pull against to get the group to move toward a particular decision, and it helps us create the most persuasive messages for that group. When we use vector modeling along with segmentation analysis, we can also compare how messaging may need to be similar or different for different groups. For example, I used segmentation analysis and then perceptual mapping and vector message modeling to understand how medical mistrust might affect the decision to get vaccinated for COVID-19 among a group of Philadelphians who had not yet been vaccinated. Our team then looked at perceptual maps and vector message modeling by levels of mistrust. The vectors showed that those with high levels of medical mistrust would be more likely to respond to messages that addressed concerns about the pandemic being a hoax, or the worry that minorities wouldn't get the same treatment as others. This allowed us to think about how to build in messages around those issues in public media campaigns or other communication strategies that encourage vaccination. I have used these methods to create and test a number of different communication strategies to influence health decisions. For example, I've developed web-based tools that have been used in hospitals and clinics in Philadelphia to encourage methadone patients with hepatitis C to receive antiviral treatment for their infection, Black cancer patients to take part in a clinical trial or to get genetic testing, and patients with low literacy and higher risk of colorectal cancer to have a colonoscopy. My colleagues and I have also developed posters, booklets and social media posts that encourage low-income and vaccine-hesitant Philadelphians in Kensington to get COVID-19 booster shots; educational slides for low-literacy Philadelphia adults on dirty bombs and how the radioactive weapons might be used in a terror attack; and a comic book for trans women to learn about the benefits of PrEP use. Getting people to make better decisions about their health can be an uphill battle. We all have our reasons for not doing things that are good for us. For example, what did you eat for lunch today? Was it healthy? If not, why did you eat it? My job is to figure out what makes people do what they do, and then help them make decisions that keep them healthy. Read more of our stories about Philadelphia. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Sarah Bauerle Bass, Temple University Read more: Philly residents with opioid addiction get medication from the 'bupe bus' − creating a path for treatment Immigrant moms feel unsafe and unheard when seeking pregnancy care – here's how they'd improve Philly's health care system Mpox, AIDS and COVID-19 show the challenges of targeting public health messaging to specific groups without causing stigma Sarah Bauerle Bass has received funding from a number of organizations, including the National Institutes of Health, the American Cancer Society, Pennsylvania and Philadelphia Departments of Health, and independent pharma research grants from Gilead and Merck.
Associated Press
3 hours ago
- Associated Press
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50. 'We are pleased to announce the addition of these patents as we continue to execute on our strategy to broaden Lexaria's patent portfolio. We believe that this not only increases our likelihood of entering into commercial deals within the pharmaceutical industry, but that it also serves as an important building block for establishing and protecting long-term value for our shareholders and all stakeholders,' said Rich Christopher, CEO of Lexaria. 'The achievement of 50 worldwide patents marks the accomplishment of a milestone that had been envisioned by the Company's management for over a decade.' Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria's intellectual property protection for the use of its DehydraTECH™ enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044. Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043. The epilepsy drug market was US$9.5 billion in 2023 and is expected to reach sales of over $15 billion by 2032. Approximately 50 million people in the US alone are affected by epilepsy. The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at 26%/yr until at least 2030, with additional revenue generated within the medically-prescribed market. The nicotine pouch market alone - where DehydraTECH™ has demonstrated absorption benefits in earlier studies - is expected to reach US$25.4 billion in revenue by 2030. Altria Ventures Inc. the 16.67% shareholder of Lexaria Nicotine LLC, holds a non-exclusive license to the use of DehydraTECH with nicotine products. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. press release
